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Abstract
The genes encoding drug-metabolizing enzymes and transporters play an important role in maintaining the
normal life processes of human body. Their disorder or defect will lead to the occurrence and development of
various diseases. Currently, most of studies have focused on genetic variations in these genes, however, in the
present study, we analyzed promoter methylation of 11 drug metabolism and transport genes in a cohort of
nodular goiter and normal thyroid tissues using methylation-specific PCR (MSP). Our data first revealed a distinct
methylation profiling in drug metabolism and transport genes between nodular goiter and normal thyroid tissues,
particularly ABCB4, CYP1B1 and CYP24A1 and SLC1A2. Given these genes contribute to the development and
progression of various diseases, such as multidrug resistance and tumorigenesis, these epigenetic events may thus
play a critical role in the pathogenesis of nodular goiter.
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Findings
The genes encoding drug-metabolizing enzymes and
transporters play an important role in transporting var-
ious kinds of molecules import or export the cells,
which is closely associated with the development of var-
ious human diseases, mainly including solute carrier
(SLC) superfamily, cytochrome P450 (CYP) superfamily
and ATP binding cassette (ABC) superfamily [1]. To
date, most of studies focused on investigating SNPs or
gene mutation in these genes, however, it is has recently
been reported that epigenetic mechanisms were involved
in the regulation of these genes [2]. In the present study,
we choose 11 drug metabolism and transport genes,
including ABCB1, ABCB4, ABCG2, CYP1A1, CYP1B1,
CYP24A1, CYP27B1, CYP39A1, SLC1A2, SLC19A3, and
SLC26A2, to detect their methylation status of promoter
region in a cohort of nodular goiter and normal thyroid
tissues using methylation-specific PCR (MSP).
Methylation analysis of thyroid tissues was carried out
in a series of 27 nodular goiter and 23 normal thyroid
paraffin-embedded tissues, which were obtained from the
Department of Pathology of the First Affiliated Hospital
of Xi’an Jiaotong University School of Medicine. All sam-
ples underwent histological examination by a senior
pathologist. The genomic DNA was isolated from paraf-
fin-embedded tissues using xylene to remove the paraffin
and sodium dodecyl sulfate (SDS) and proteinase K to
digest tissues, followed by standard phenol-chloroform
extraction and ethanol precipitation of DNA. DNA was
subsequently treated with sodium bisulfite to detect the
methylation status of these 11 genes using methylation-
specific PCR (MSP) as described previously [3]. Normal
leukocyte DNA was methylated in vitro with Sss I methy-
lase (New England Biolabs, Beverly, MA) to generate
completely methylated DNA as a positive control. The
primer sequences and their annealing temperatures were
presented in Table 1. To examine the role of DNA
methylation in the regulation of gene expression, we trea-
ted 3 thyroid cancer cell lines, including FTC133, K1, and
C643, with 5 μM demethylation agent 5-Aza-2’-dC for 5
days to induce the expression of the methylated genes.
SPSS17.0 software was used for data analysis, and data
were compared using chi-square test or the t test. The
risk of gene methylation to the various clinical variates,
including age, gender, a family history of thyroid disease
(such as Graves’ disease, goiter, thyroid adenoma and
hashimoto thyroiditis (HT); the members include the
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patient’s immediate families within 3 generations), and
the level of Tg and TSH, was analyzed using the logistic
regression. P values < 0.05 were considered significant.
As shown in Figures 1 and 2, 8 of 11 genes were methy-
lated in nodular goiter tissues, ranging from 3.7% to
29.6%. Ten of 11 genes were methylated in normal thyroid
tissues, ranging from 4.4% to 82.6%. The methylation rate
of these genes, except for CYP1A1, was higher in normal
thyroid tissues than nodular goiter tissues. Among of
them, there was a significantly distinct methylation profil-
ing of ABCB4, CYP1B1 and CYP24A1 and SLC1A2
between nodular goiter and normal thyroid tissues (P <
0.05) (Figure 2). Promoter methylation of ABCG2 was sig-
nificantly positively associated with a family history of
thyroid diseases (P < 0.05). The multivariable analyses
showed that no significant difference was found between
gene methylation and age, gender, a family history of thyr-
oid disease, and the level of Tg and TSH (data not shown).
To date, most of studies have focused on polymorph-
isms (e.g. SNPs) or gene mutation in drug metabolism and
transport genes in some human diseases, including thyroid
disease, such as Graves’ disease [4]. Unlike the previous
studies, this study systematically analyzed promoter
methylation of drug metabolism and transport genes in
nodular goiter tissues. Promoter methylation is the most
common epigenetic events that aberrantly regulate gene
expression in different tissues, which play a key role in the
early disease [5]. The pathogenesis of nodular goiter is
multifactorial and probably differs from patient to patient.
In contrast to the endemic goiter, iodine deficiency is not
a primary causal factor. Environmental factors, such as
natural goitrogens, iodine intake, malnutrition, drugs,
stress, pollution or infections, constitutional factors, such
as female gender, and several genetic factors, such as cir-
culating thyroid growth factors, contribute to different
degree to the development of nodular thyroid enlarge-
ment. However, in the present study, our data suggested
that aberrant methylation of some genes, such as drug
metabolism and transport genes, may play an important
role in the pathogenesis of nodular goiter. In support of
this, a previous study also showed that the Platelet-derived
growth factor B-chain was also abnormally methylated in
multinodular goiters [6].
ABCB4 belongs to the multidrug resistance subfamily,
encoding a full transporter and member of the p-glycopro-
tein family of membrane proteins with phosphatidylcholine
as its substrate [7], which was more frequently methylated
in normal thyroid tissue compared with nodular goiter in
the present study. Of note, this gene was highly expressed
in various human cancers [8,9]. Its overexpression may
Table 1 Methylation-specific PCR (MSP) primers used in the present study
Genes Allele Forward (5’®3’) Reverse (5’®3’) Length (bp) Annealing temperature (°C)
ABCB1 M CGAGGAATTAGTATTTAGTTAATTCGGGTCGG ACTCAACCCACGCCCCGACG 95 60
U TGAGGAATTAGTATTTAGTTAATTTGGGTTGG ACTCAACCCACACCCCAACA 95 57
ABCB4 M GGTAAGAGCGGTAGGTTGC GAAAAACGCCTACCGTTACA 121 59
U GGTAAGAGTGGTAGGTTGT AAAAAACACCTACCATTACA 121 55
ABCG2 M ATTTGTGCGTTAGCGTTTTC CTCCGAAATCGAACGAAATA 149 59
U GTAATTTGTGTGTTAGTGTTTTT CCTCCAAAATCAAACAAAATAAA 149 57
CYP1A1 M TCGGCGTACGTAAGTTAGTC AAACACAAAAATCCGACGA 113 59
U GTTGGTGTATGTAAGTTAGTT AAAACACAAAAATCCAACAA 113 56
CYP1B1 M CGCGTTTTTAAGTCGAGC ACCCACGTTTCCATTATACG 125 58
U GGGTGTGTTTTTAAGTTGAGT ACCCACATTTCCATTATACAATA 125 56
CYP24A1 M ATGTTTTGAGGTTGTCGC AAAATCGAAACTTAACGATTCT 140 57
U TTAATGTTTTGAGGTTGTTGT AAAATCAAAACTTAACAATTCTAAA 140 55
CYP27B1 M TTAGAGTGTTTTATCGCGTTC CTCGTATAACCTCGACAACC 164 58
U TTTTTAGAGTGTTTTATTGTGTTT AACTCATATAACCTCAACAACCC 164 55
CYP39A1 M TAATGTAGTTCGTCGGGTTTC AACCAACGCGAAAAAAATAC 152 59
U GGGTAATGTAGTTTGTTGGGTTTT CAACCAACACAAAAAAAATACAA 152 57
SLC1A2 M AGTTGAAGCGGGTGTTTC GAAATAAAACGCAAACGACC 110 58
U AGTTGAAGTGGGTGTTTT AAAATAAAACACAAACAACC 110 57
SLC19A3 M GTTTGGACGTTCGGATTC CGCGACTATCGAATAAATCC 114 57
U AAGGTTTGGATGTTTGGATTT ACCCACAACTATCAAATAAATCC 114 55
SLC26A2 M GAGGTGGTCGATCGTAAAC CGTAACGTTAACTCCTCCG 139 59
U AAAGAGGTGGTTGATTGTAAAT TCCATAACATTAACTCCTCCAC 139 57
M, mehthylation-specific primers; U, unmenthylation-specific primers
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induce multidrug resistance and create a waste of energy
[7]. CYP1B1 belongs to the cytochrome P450 family 1 and
is a major member of the extrahepatic xenobiotic-metabo-
lizing CYP enzyme family. It can transform estrogen to
strong carcinogenic compounds 4-hydroxy estrogen, and is
overexpressed in various malignant tumors, and promotes
the development of tumors [10,11]. CYP1B1 was signifi-
cantly lowly methylated in nodular goiter compared with
normal thyroid tissues in the present study, suggesting that
its aberrant expression may play a key role in in the patho-
genesis of nodular goiter. CYP24A1 is relevant with the
metabolism of vitamin D3, which emerged as a protective
factor for human body. CYP24A1 encodes a mitochondrial
protein which initiates the degradation of 1,25-dihydroxyvi-
tamin D3, the physiologically active form of vitamin D3, by
hydroxylation of the side chain [12]. A previous study
showed that the administration of calcitriol in combination
with CYP24A1 inhibitor enhanced antiproliferative effects,
Figure 1 Representative MSP results of 8 drug metabolism and transport genes in PTC. In vitro methylated DNA was used as positive
control for methylated gene (P), bisulfite-modified normal leukocyte DNA as positive control for unmethylated gene (N), and H2O as blank
control to confirm the specificity of MSP. M, methylated gene; U, unmethylated gene.
Figure 2 The methylation frequency of 11 drug metabolism and transport genes in nodular goiter and normal thyroid tissues. A total
of 27 nodular goiter and 23 normal thyroid tissues were analyzed for this study. MSP was used to detect promoter methylation of 11 genes,
including ABCB1, ABCB4, ABCG2, SLC1A2, SLC19A3, SLC26A2, CYP1A1, CYP1B1, CYP24A1, CYP27B1 and CYP39A1. *, P < 0.05.
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increased systemic calcitriol exposure, and promoted the
activation of caspase-independent apoptosis pathway [13].
Interestingly, a very recent study showed that that
CYP24A1 expression is marked increased in papillary thyr-
oid cancer (PTC) compared with normal thyroid tissues
[14]. It is consistent with our recent findings that CYP24A1
was significantly lowly methylated in PTC compared with
normal tissues (Lihong Zhang, Jing Shi, Meiju Ji, Guanjun
Zhang, Jiao Fu, Li Xu, Bingyin Shi, and Peng Hou: Methy-
lation analysis of drug metabolism and transport genes in
papillary thyroid cancer, submitted). SLC1A2 encodes a
membrane-bound protein which is the principal transpor-
ter that clears the excitatory neurotransmitter glutamate
from the extracellular space at synapses in the central ner-
vous system, to prevent neuronal damage from excessive
activation of glutamate receptors [15]. Importantly, our
data showed that demethylation agent 5-Aza-2’-dC could
induce the expression of these methylated genes in at least
one cell line, indicating that expression of these genes
could be regulated by promoter methylation (data not
shown).
In conclusions, although nodular goiter is a benign
disease, it seriously influences the quality of life of many
patients because it usually causes dyspnea and swallow-
ing difficulties. Thus, it is amazing if we can inhibit the
occurrence or proceeding of this disease. In the present
study, we observed that a distinct methylation profiling
in drug metabolism and transport genes between nodu-
lar goiter and normal thyroid tissues, suggesting that
aberrant expression of these genes may play an impor-
tant role in the pathogenesis of nodular goiter.
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